Actively Recruiting

Age: 18Years +
All Genders
ID05880537

Safety and Effectiveness of Decellularized Femoral Artery Allograft for Hemodialysis Access in End-Stage Renal Disease: A Multi-center Prospective Registry Study

Led by LifeNet Health · Updated on 2025-04-02

100

Participants Needed

4

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are assessing the safety and effectiveness of a decellularized human femoral artery allograft called Nexeon AVX for creating vascular access in patients with End-Stage Renal Disease (ESRD) who require hemodialysis. This prospective, observational post-market registry study aims to gather real-world data on this novel allograft's use in hemodialysis access. Participants will receive the Nexeon AVX allograft as part of their vascular access for hemodialysis. The study is open-label and involves patients with ESRD who need dialysis access where placement of an arteriovenous access graft is suitable. There are no comparator groups since this is an observational registry tracking outcomes after graft placement. During the study, participants will undergo ultrasound evaluations over 24 months to monitor the functional patency of the allograft. Researchers will collect safety and efficacy data, including additional secondary outcomes over the same duration. Participants are expected to return for scheduled assessments, and data will be collected to evaluate the graft's performance and any safety concerns over the two-year period.

CONDITIONS

Brief Title

Decellularized Femoral Artery Allograft (Nexeon AVX) Prospective Registry

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Be male or female aged 18 years or older at the time of graft placement
  • Have a diagnosis of End-Stage Renal Disease or kidney dysfunction requiring hemodialysis
  • Need dialysis access to start or maintain dialysis where an arteriovenous graft is a suitable option
  • Be able to understand the study, provide written informed consent, and agree to follow study requirements
  • Have provided written authorization for use and disclosure of protected health information
Not Eligible

You will not qualify if you...

  • Currently participating in another investigational drug or device study
  • Known sensitivity to processing reagents used in the graft manufacturing, including certain antibiotics and chemicals
  • History or evidence of severe heart disease, recent heart attack within 6 months, dangerous heart rhythms, or unstable angina needing ongoing treatment
  • History or evidence of severe peripheral vascular disease in the upper limbs
  • Unable or unwilling to follow the study visit schedule
  • Any condition that the investigator believes poses undue risk or may affect study data quality

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Implementation

Duration - Single procedure at enrollment

Participants receive a decellularized human femoral artery allograft to create vascular access for hemodialysis.

1 visit (in-person) for graft placement

Long-term Monitoring

Duration - Up to 24 months

Participants are monitored for up to 24 months to assess the safety and effectiveness of the allograft through ultrasound evaluations of graft patency.

Periodic visits for ultrasound evaluations up to 24 months

Trial Site Locations

Total: 4 locations

1

Infirmary Heath

Mobile, Alabama, United States, 36607

Actively Recruiting

2

Olive View - UCLA Medical Center

Sylmar, California, United States, 91342

Actively Recruiting

3

Harbor-UCLA Medical Center

Torrance, California, United States, 90502

Actively Recruiting

4

Sentara Norfolk General Hospital

Norfolk, Virginia, United States, 23507

Actively Recruiting

Loading map...

Research Team

K

Kimberly Dorsch

M

Monique Alston-Epps

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Similar Trials

An Open-Label, Single-Dose Study to Evaluate MK-2828 Pharmac...

Chronic Kidney Failure

Actively Recruiting

3 locations

Comparative Study of Automated Peritoneal Dialysis With Remo...

End-stage Renal Disease

Actively Recruiting

1 location

Phase 1/2 Single-Arm Open-Label Trial Evaluating Safety and ...

End-Stage Renal Disease

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here